Mirdametinib for infants and toddlers with NF1 tumors
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a study drug called mirdametinib in infants and toddlers who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas (non-cancerous nerve tumors). The study aims to see if the drug can shrink or control these tumors, which may help prevent or reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between birth and 21 months old (adjusted for prematurity).
- Your child must have a confirmed diagnosis of NF1, based on clinical guidelines, and have at least one plexiform neurofibroma (a type of nerve tumor).
- The tumor must be measurable on an MRI and be at least 3 mL in volume.
- The tumor must be either in a high-risk location (like head/neck, spine, or near vital organs) or causing symptoms like pain, breathing issues, or disfigurement.
- Your child must not have had certain previous treatments for NF1 tumors within the last 28 days.
- Your child must not be taking certain medications that could interfere with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to an investigational drug called mirdametinib for people with serious, debilitating, or life-threatening conditions who have no other treatment options and cannot join a clinical trial. It aims to offer a potential treatment when nothing else has worked.
This study tests an oral drug called mirdametinib to see if it can shrink skin bumps caused by NF1. If you have at least 24 of these bumps on your skin and are in decent health, you may be able to join.
This trial tests a drug called mirdametinib, which targets a protein linked to tumor growth, given alone or with radiation. It is for people with certain brain or spinal cord tumors, especially those with a condition called NF1, to see if it can help control the cancer.
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a low dose of a drug called selumetinib for children with NF1 who have plexiform neurofibromas that cannot be surgically removed. The goal is to see if this drug can help shrink or slow the growth of these tumors.
Hear when a new Neurofibromatosis Type 1-Associated Plexiform Neurofibromas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.